^
Association details:
| Biomarker: | FBXW7 deletion |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Zolinza (vorinostat) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma
Excerpt:
To test directly whether loss of FBW7 function confers sensitivity to vorinostat we used siRNA to ablate FBW7 expression in KYSE-150 cells, which are vorinostat-resistant at baseline. As predicted, FBW7 ablation significantly increased apoptosis and decreased viable cell numbers in multiple SCC cell lines following vorinostat treatment (Fig. 3E and Supplementary Fig. S3A). Thus FBW7 loss-of-function increases Mcl-1 stability and vorinostat sensitivity in SCC cells.
DOI:
10.1158/2159-8290.CD-12-0417
